Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.43 |
| ▸ | PARP6 | Q2NL67 | 3/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 3/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 3/20 | 0.41 |
| ▸ | USP25 | Q9UHP3 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413985 | 0.94 | USP28 (0.39) | PARP1PARP2PARP6PARP3USP28 | |
| SCHEMBL29394098 | 0.92 | PARP1 (0.48) | PARP1PARP2PARP6PARP3USP28 | |
| SCHEMBL22912735 | 0.92 | PARP1 (0.48) | PARP1PARP2PARP6PARP3USP28 | |
| Hydrochloric Acid SCHEMBL27202730 | 0.91 | PARP1 (0.48) | PARP1PARP2PARP6PARP3USP28 | |
| Hydrochloric Acid SCHEMBL29396466 | 0.91 | PARP1 (0.48) | PARP1PARP2PARP6PARP3USP28 | |
| Hydrochloric Acid SCHEMBL25236649 | 0.91 | PARP1 (0.48) | PARP1PARP2PARP6PARP3USP28 | |
| Hydrochloric Acid SCHEMBL30413282 | 0.91 | PARP1 (0.48) | PARP1PARP2PARP6PARP3USP28 | |
| Hydrochloric Acid SCHEMBL30218612 | 0.87 | PARP1 (0.41) | PARP1PARP2PARP6PARP3USP28 | |
| Hydrochloric Acid SCHEMBL30218629 | 0.87 | PARP1 (0.41) | PARP1PARP2PARP6PARP3USP28 | |
| SCHEMBL22912708 | 0.83 | PARP1 (0.49) | PARP1PARP2PARP6PARP3USP28 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| WO-2024178127-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 4/4885PARP6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.